Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 1:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo - Placebo Clear all
Completed Phase 2 Interventional

Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

NCT04683848
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
MT-3921, Placebo
Biological
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
Orange, California • Tallahassee, Florida • Augusta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 28, 2026, 1:18 PM EDT
Completed Phase 3 Interventional Results available

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)

NCT02709655
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20mg/day, Placebo
Drug · Other
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
7 Years to 11 Years
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
34
States / cities
Little Rock, Arkansas • Imperial, California • Lemon Grove, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Sep 28, 2026, 1:18 PM EDT
Terminated Phase 2 Interventional Results available

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment

NCT01521143
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Cvac, Placebo
Biological
Lead sponsor
Prima BioMed Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
6
States / cities
Los Angeles, California • Boynton Beach, Florida • Sarasota, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Sep 28, 2026, 1:18 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma

NCT01316315
View directory record Official record
Conditions
Asthma
Interventions
Active, Placebo
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Denver, Colorado • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 4, 2014 · Synced Sep 28, 2026, 1:18 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus

NCT02725515
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
XmAb5871, Placebo to match XmAb5871
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
La Jolla, California • Loma Linda, California • San Leandro, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 28, 2026, 1:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cognitive Effects of Citicoline in Men and Women With Age-Associated Memory Impairment

NCT03369925
View directory record Official record
Conditions
Healthy
Interventions
Placebo supplement, Citicoline supplement
Dietary Supplement
Lead sponsor
Kyowa Hakko Bio Co., Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Sep 28, 2026, 1:18 PM EDT
Completed Phase 2 Interventional Results available

A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.

NCT00175825
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, Brivaracetam
Other · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Sep 28, 2026, 1:18 PM EDT
Completed Phase 1 Interventional

Study to Evaluate DNL151 in Subjects With Parkinson's Disease

NCT04056689
View directory record Official record
Conditions
Parkinson's Disease
Interventions
DNL151, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
30 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Orlando, Florida • Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 28, 2026, 1:18 PM EDT
Completed Phase 3 Interventional

A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)

NCT03398005
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
CaPre, Placebo
Drug
Lead sponsor
Grace Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
69
States / cities
Birmingham, Alabama • Tucson, Arizona • Conway, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 28, 2026, 1:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adult Volunteers to Assess the Safety and Pharmacokinetics of an Investigational Imaging Product

NCT03698305
View directory record Official record
Conditions
Healthy Subjects
Interventions
ASP5354, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 28, 2026, 1:18 PM EDT
Terminated Phase 2 Interventional

A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia

NCT00176566
View directory record Official record
Conditions
Oral Leukoplakia
Interventions
Lozenge Intake
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2009 · Synced Sep 28, 2026, 1:18 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection

NCT05784129
View directory record Official record
Conditions
Crohn's Disease
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
9
States / cities
San Diego, California • Naples, Florida • Macon, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 28, 2026, 1:18 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oral T7 Oral Testosterone in Man

NCT00842751
View directory record Official record
Conditions
Healthy Males, Male Contraceptive
Interventions
First Intervention (7 days), First Washout (7 days), Second Intervention (7 days), Third Intervention (7 days), Second wash-out period
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Sep 28, 2026, 1:18 PM EDT
Completed Phase 2 Interventional Results available

Eltrombopag for Post Transplant Thrombocytopenia

NCT01000051
View directory record Official record
Conditions
Thrombocytopenia
Interventions
Eltrombopag, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Sep 28, 2026, 1:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Staccato Loxapine Thorough QT/QTc Study

NCT00874237
View directory record Official record
Conditions
Thorough QT/QTc Study
Interventions
Inhaled loxapine, Inhaled placebo, Oral moxifloxacin, Oral placebo
Drug
Lead sponsor
Nova Pneuma Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 28, 2026, 1:18 PM EDT
Withdrawn Phase 2 Interventional

PRO 140 for Human Immunodeficiency Virus

NCT02438345
View directory record Official record
Conditions
HIV
Interventions
PRO 140
Biological
Lead sponsor
Drexel University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Phildadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 28, 2026, 1:18 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis

NCT00750139
View directory record Official record
Conditions
Tinea Pedis, Athlete's Foot
Interventions
NAFT-500, Placebo 2-weeks, Naftin 1%, Placebo 4-weeks
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
707 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Sep 28, 2026, 1:18 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis

NCT00573157
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Atacicept, Mycophenolate mofetil, Placebo, Corticosteroids
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
16 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
12
States / cities
New Orleans, Louisiana • Shreveport, Louisiana • Detroit, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Sep 28, 2026, 1:18 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Pilot Study of Oxaloacetate in Subjects With Treated PD

NCT01741701
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Oxaloacetate (OAA), Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
30 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 28, 2026, 1:18 PM EDT
Completed Phase 2 Interventional Results available

Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability

NCT02002819
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
levetiracetam
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
45 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
San Francisco, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Sep 28, 2026, 1:18 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pharmacotherapy & CM for Opioid and Cocaine Dependence

NCT00838981
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Modafinil, Sugar Pill, Contingency Management, Methadone, cognitive behavioral treatment, Voucher Control
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Sep 28, 2026, 1:18 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease

NCT02970019
View directory record Official record
Conditions
Parkinson Disease
Interventions
K0706, Placebo
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Long Beach, California • Panorama City, California • DeLand, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 28, 2026, 1:18 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT00603265
View directory record Official record
Conditions
Peripheral Neuropathy, Neuropathic Pain
Interventions
ADL5859, Duloxetine, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Riverside, California • Torrance, California • Kissimmee, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Sep 28, 2026, 1:18 PM EDT
Completed Phase 2 Interventional Results available

Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)

NCT02147067
View directory record Official record
Conditions
Microvascular Angina
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Sep 28, 2026, 1:18 PM EDT